Correlation Between CRISPR Therapeutics and Citigroup

Can any of the company-specific risk be diversified away by investing in both CRISPR Therapeutics and Citigroup at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CRISPR Therapeutics and Citigroup into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between CRISPR Therapeutics AG and Citigroup, you can compare the effects of market volatilities on CRISPR Therapeutics and Citigroup and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CRISPR Therapeutics with a short position of Citigroup. Check out your portfolio center. Please also check ongoing floating volatility patterns of CRISPR Therapeutics and Citigroup.

Diversification Opportunities for CRISPR Therapeutics and Citigroup

-0.32

Correlation Coefficient

CRISPR Therapeutics  Citigroup

Very good diversification

The 3 months correlation between CRISPR and Citigroup is -0.32. Overlapping area represents the amount of risk that can be diversified away by holding CRISPR Therapeutics AG and Citigroup in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Citigroup and CRISPR Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CRISPR Therapeutics AG are associated (or correlated) with Citigroup. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Citigroup has no effect on the direction of CRISPR Therapeutics i.e., CRISPR Therapeutics and Citigroup go up and down completely randomly.

Pair Corralation between CRISPR Therapeutics and Citigroup

Assuming the 90 days trading horizon CRISPR Therapeutics is expected to generate 25.39 times less return on investment than Citigroup. In addition to that, CRISPR Therapeutics is 1.99 times more volatile than Citigroup. It trades about 0.01 of its total potential returns per unit of risk. Citigroup is currently generating about 0.25 per unit of volatility. If you would invest  7,365  in Citigroup on October 25, 2024 and sell it today you would earn a total of  673.00  from holding Citigroup or generate 9.14% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

CRISPR Therapeutics AG  vs.  Citigroup

CRISPR Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CRISPR Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Citigroup

Risk-Adjusted Performance

23 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Citigroup are ranked lower than 23 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak technical and fundamental indicators, Citigroup sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with CRISPR Therapeutics and Citigroup

The main advantage of trading using opposite CRISPR Therapeutics and Citigroup positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CRISPR Therapeutics position performs unexpectedly, Citigroup can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citigroup will offset losses from the drop in Citigroup's long position.

The idea behind CRISPR Therapeutics AG and Citigroup pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.